newsfilter
← Latest News
GlobeNewswire·

BiondVax Announces Closing of $8 Million Underwritten Public Offering

JERUSALEM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)("Company"), a biotechnology company, which focuses on developing, manufacturing, and commercializing